Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

175 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Cyclooxygenase-2 as a target for anticancer drug development.
Méric JB, Rottey S, Olaussen K, Soria JC, Khayat D, Rixe O, Spano JP. Méric JB, et al. Among authors: rottey s. Crit Rev Oncol Hematol. 2006 Jul;59(1):51-64. doi: 10.1016/j.critrevonc.2006.01.003. Epub 2006 Mar 13. Crit Rev Oncol Hematol. 2006. PMID: 16531064 Review.
Phase I Dose-Escalation Study of the Anti-CD70 Antibody ARGX-110 in Advanced Malignancies.
Aftimos P, Rolfo C, Rottey S, Offner F, Bron D, Maerevoet M, Soria JC, Moshir M, Dreier T, Van Rompaey L, Michot JM, Silence K, Hultberg A, Gandini D, de Haard H, Ribrag V, Peeters M, Thibault A, Leupin N, Awada A. Aftimos P, et al. Among authors: rottey s. Clin Cancer Res. 2017 Nov 1;23(21):6411-6420. doi: 10.1158/1078-0432.CCR-17-0613. Epub 2017 Aug 1. Clin Cancer Res. 2017. PMID: 28765328 Clinical Trial.
Phase II study of everolimus in patients with locally advanced or metastatic transitional cell carcinoma of the urothelial tract: clinical activity, molecular response, and biomarkers.
Seront E, Rottey S, Sautois B, Kerger J, D'Hondt LA, Verschaeve V, Canon JL, Dopchie C, Vandenbulcke JM, Whenham N, Goeminne JC, Clausse M, Verhoeven D, Glorieux P, Branders S, Dupont P, Schoonjans J, Feron O, Machiels JP. Seront E, et al. Among authors: rottey s. Ann Oncol. 2012 Oct;23(10):2663-2670. doi: 10.1093/annonc/mds057. Epub 2012 Apr 3. Ann Oncol. 2012. PMID: 22473592 Free article. Clinical Trial.
Selective Oral MEK1/2 Inhibitor Pimasertib: A Phase I Trial in Patients with Advanced Solid Tumors.
Delord JP, Italiano A, Awada A, Aftimos P, Houédé N, Lebbé C, Pages C, Lesimple T, Dinulescu M, Schellens JHM, Leijen S, Rottey S, Kruse V, Kefford R, Faivre S, Gomez-Roca C, Scheuler A, Massimini G, Raymond E. Delord JP, et al. Among authors: rottey s. Target Oncol. 2021 Jan;16(1):37-46. doi: 10.1007/s11523-020-00768-0. Target Oncol. 2021. PMID: 33170484 Clinical Trial.
A randomized, double-blind, placebo-controlled study to assess QTc interval prolongation of standard dose aflibercept in cancer patients treated with docetaxel.
Maison-Blanche P, Vermorken JB, Goksel T, Machiels JP, Agarwala S, Rottey S, Daugaard G, Volovat C, Scheulen M, Sengeløv L, Grecea D, Eniu A, Jäger E, Meiri E, Cascinu S, Strumberg D, Demir G, Clemens M, Pinotti G, Nardi M, Guthrie T, Boelle E, Magherini E. Maison-Blanche P, et al. Among authors: rottey s. J Cardiovasc Pharmacol. 2013 Jun;61(6):495-504. doi: 10.1097/FJC.0b013e31828b73ff. J Cardiovasc Pharmacol. 2013. PMID: 23429593 Clinical Trial.
An open-label study to investigate the cardiac safety profile of cabazitaxel in patients with advanced solid tumors.
Maison-Blanche P, Dakhil S, Baron A, Rottey S, Millard F, Daugaard G, Machiels JP, Conkright W, Sharma S, Soetekouw PM, Yachnin J, Sengeløv L, Van Veldhuizen P, Agarwala SS, Sémiond D, Chadjaa M, Shen L, Wade JL. Maison-Blanche P, et al. Among authors: rottey s. Cancer Chemother Pharmacol. 2014 Jun;73(6):1241-52. doi: 10.1007/s00280-014-2460-6. Epub 2014 Apr 10. Cancer Chemother Pharmacol. 2014. PMID: 24718982 Clinical Trial.
On-Target Pharmacodynamic Activity of the PI3K Inhibitor Copanlisib in Paired Biopsies from Patients with Malignant Lymphoma and Advanced Solid Tumors.
Morschhauser F, Machiels JP, Salles G, Rottey S, Rule SAJ, Cunningham D, Peyrade F, Fruchart C, Arkenau HT, Genvresse I, Liu L, Köchert K, Shen K, Kneip C, Peña CE, Grevel J, Zhang J, Cisternas G, Reschke S, Granvil C, Awada A. Morschhauser F, et al. Among authors: rottey s. Mol Cancer Ther. 2020 Feb;19(2):468-478. doi: 10.1158/1535-7163.MCT-19-0466. Epub 2019 Oct 16. Mol Cancer Ther. 2020. PMID: 31619463 Clinical Trial.
CD70: An emerging target in cancer immunotherapy.
Jacobs J, Deschoolmeester V, Zwaenepoel K, Rolfo C, Silence K, Rottey S, Lardon F, Smits E, Pauwels P. Jacobs J, et al. Among authors: rottey s. Pharmacol Ther. 2015 Nov;155:1-10. doi: 10.1016/j.pharmthera.2015.07.007. Epub 2015 Jul 26. Pharmacol Ther. 2015. PMID: 26213107 Review.
Preclinical data on the combination of cisplatin and anti-CD70 therapy in non-small cell lung cancer as an excellent match in the era of combination therapy.
Jacobs J, Deschoolmeester V, Rolfo C, Zwaenepoel K, Van den Bossche J, Deben C, Silence K, de Haard H, Hermans C, Rottey S, Vangestel C, Lardon F, Smits E, Pauwels P. Jacobs J, et al. Among authors: rottey s. Oncotarget. 2017 May 23;8(43):74058-74067. doi: 10.18632/oncotarget.18202. eCollection 2017 Sep 26. Oncotarget. 2017. PMID: 29088768 Free PMC article.
175 results